Related Experiment Video
Updated: Feb 10, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
Novel approach to temozolomide resistance in malignant glioma: connexin43-directed therapeutics
Christina L Grek1, Zhi Sheng2, Christian C Naus3
1FirstString Research, Inc., Mount Pleasant, SC, USA.
Abstract:
Resistance of malignant glioma, including glioblastoma (GBM), to the chemotherapeutic temozolomide (TMZ) remains a key obstacle in treatment strategies. The gap junction protein connexin43 (Cx43) has complex roles in the establishment, progression, and persistence of malignant glioma. Recent findings demonstrate that connexins play an important role in the microenvironment of malignant glioma and that Cx43 is capable of conferring chemotherapeutic resistance to GBM cells. Carboxyl-terminal Cx43 peptidomimetics show therapeutic promise in overcoming TMZ resistance via mechanisms that may include modulating junctional activity between tumor cells and peritumoral cells and/or downstream molecular signaling events mediated by Cx43 protein binding. High levels of intra-tumor and inter-tumor heterogeneity make it difficult to clearly define specific populations for Cx43-targeted therapy; hence, development of in vitro models that better mimic the microenvironment of malignant glioma, and the incorporation of patient-derived stem cells, could provide opportunities for patient-specific drug screening. This review summarizes recent advances in understanding the roles of Cx43 in malignant glioma, with a special focus on tumor microenvironment, TMZ resistance, and therapeutic opportunity offered by Cx43 peptidomimetics.
Insights
Connexin43 (Cx43) protein contributes to glioblastoma (GBM) resistance to temozolomide (TMZ) chemotherapy. Cx43 peptidomimetics offer a promising therapeutic strategy to overcome this resistance, potentially through modulating tumor microenvironment interactions.
Area of Science:
- Neuro-oncology
- Molecular biology
- Cancer therapeutics
Background:
- Malignant glioma, particularly glioblastoma (GBM), exhibits significant resistance to temozolomide (TMZ) chemotherapy.
- The gap junction protein connexin43 (Cx43) plays a multifaceted role in glioma development and progression.
- Cx43 is implicated in conferring chemotherapeutic resistance to GBM cells and influencing the tumor microenvironment.
Purpose of the Study:
- To review recent advancements in understanding the role of Cx43 in malignant glioma.
- To highlight Cx43's involvement in the tumor microenvironment and TMZ resistance.
- To explore the therapeutic potential of Cx43 peptidomimetics in overcoming TMZ resistance.
Main Methods:
- Literature review focusing on Cx43, malignant glioma, tumor microenvironment, and temozolomide resistance.
- Analysis of studies investigating Cx43 peptidomimetics as a therapeutic strategy.
- Discussion of in vitro models and patient-derived stem cells for personalized drug screening.
Main Results:
- Cx43 contributes to TMZ resistance in GBM, potentially by influencing cell-cell communication and signaling pathways.
- Cx43 peptidomimetics demonstrate therapeutic promise in preclinical models of TMZ-resistant glioma.
- Tumor heterogeneity presents challenges for targeted Cx43 therapies, emphasizing the need for advanced in vitro models.
Conclusions:
- Cx43 is a critical factor in malignant glioma's resistance to TMZ.
- Cx43 peptidomimetics represent a viable therapeutic avenue for overcoming TMZ resistance.
- Developing patient-specific in vitro models is crucial for advancing Cx43-targeted therapies and personalized treatment strategies.
Related Concept Videos
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Resistivity
Resistance
Therapeutic Index
Equivalent Resistance
Resistance and Conductance
Various factors impact the resistance of a conductor. Spiraling in stranded conductors increases their...

